- Home
- RXRX vs GERN Comparison
RXRX vs GERN Comparison
Compare RXRX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- GERN
- Stock Information
- Founded
- RXRX 2013
- GERN 1990
- Country
- RXRX United States
- GERN United States
- Employees
- RXRX N/A
- GERN N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- GERN Health Care
- Exchange
- RXRX Nasdaq
- GERN Nasdaq
- Market Cap
- RXRX 2.6B
- GERN 2.5B
- IPO Year
- RXRX 2021
- GERN 1996
- Fundamental
- Price
- RXRX $6.22
- GERN $3.77
- Analyst Decision
- RXRX Buy
- GERN Strong Buy
- Analyst Count
- RXRX 5
- GERN 10
- Target Price
- RXRX $9.25
- GERN $7.05
- AVG Volume (30 Days)
- RXRX 15.6M
- GERN 6.3M
- Earning Date
- RXRX 11-06-2024
- GERN 11-07-2024
- Dividend Yield
- RXRX N/A
- GERN N/A
- EPS Growth
- RXRX N/A
- GERN N/A
- EPS
- RXRX N/A
- GERN N/A
- Revenue
- RXRX $65,184,000.00
- GERN $29,480,000.00
- Revenue This Year
- RXRX $60.17
- GERN $32,021.10
- Revenue Next Year
- RXRX $19.88
- GERN $298.14
- P/E Ratio
- RXRX N/A
- GERN N/A
- Revenue Growth
- RXRX 37.64
- GERN 9199.68
- 52 Week Low
- RXRX $5.60
- GERN $1.64
- 52 Week High
- RXRX $15.74
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- RXRX 43.38
- GERN 38.91
- Support Level
- RXRX $6.75
- GERN $3.75
- Resistance Level
- RXRX $7.85
- GERN $4.00
- Average True Range (ATR)
- RXRX 0.79
- GERN 0.16
- MACD
- RXRX -0.07
- GERN -0.01
- Stochastic Oscillator
- RXRX 4.99
- GERN 10.42
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.